Lesson plan

CGP 52608

CGP 52608 is a selective ligand of the RAR-related orphan receptor alpha. It has been used as a biochemical tool to investigate nuclear and membrane signaling of melatonin. CGP 52608 has also been reported to possess antiarthritic activity. The pharmaceutical company Novartis brought it to clinical trials for rheumatoid arthritis, but development was discontinued in 2006. CGP 52608 contains a thiazolinidinedione group.

Back to article

Article summary

CGP 52608 is a selective ligand of the RAR-related orphan receptor alpha. It has been used as a biochemical tool to investigate nuclear and membrane signaling of melatonin. CGP 52608 has also been reported to possess antiarthritic activity. The pharmaceutical company Novartis brought it to clinical trials for rheumatoid arthritis, but development was discontinued in 2006. CGP 52608 contains a thiazolinidinedione group.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.